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ABSTRACT
Introduction Models that have so far been used to 
estimate and project the prevalence and disease burden 
of asthma are in most cases inadequately described and 
irreproducible. We aim systematically to describe and 
critique the existing models in relation to their strengths, 
limitations and reproducibility, and to determine the 
appropriate models for estimating and projecting the 
prevalence and disease burden of asthma.
Methods We will search the following electronic 
databases to identify relevant literature published from 
1980 to 2017: Medline, Embase, WHO Library and 
Information Services and Web of Science Core Collection. 
We will identify additional studies by searching the 
reference list of all the retrieved papers and contacting 
experts. We will include observational studies that used 
models for estimating and/or projecting prevalence and 
disease burden of asthma regarding human population 
of any age and sex. Two independent reviewers will 
assess the studies for inclusion and extract data from 
included papers. Data items will include authors’ names, 
publication year, study aims, data source and time period, 
study population, asthma outcomes, study methodology, 
model type, model settings, study variables, methods of 
model derivation, methods of parameter estimation and/
or projection, model fit information, key findings and 
identified research gaps. A detailed critical narrative 
synthesis of the models will be undertaken in relation to 
their strengths, limitations and reproducibility. A quality 
assessment checklist and scoring framework will be used 
to determine the appropriate models for estimating and 
projecting the prevalence anddiseaseburden of asthma.
Ethics and dissemination We will not collect any primary 
data for this review, and hence there is no need for formal 
National Health Services Research Ethics Committee 
approval. We will present our findings at scientific 
conferences and publish the findings in the peer-reviewed 
scientific journal.
BACkgRound
Asthma is now one of the most common 
long-term conditions in the world, and it is 
responsible for substantial morbidity and in 
some cases mortality.1 The overall worldwide 
trend in the prevalence of asthma appears to 
have plateaued in some parts of the world, while 
it is still increasing in some countries.2 Asthma 
has been ranked as the 14th most important 
cause of years lived with disability (YLDs) in the 
world,3 and it accounts for 1% of all disabili-
ty-adjusted life years (DALYs) lost globally.4
The societal and healthcare costs 
attributed to asthma are also high across 
different world regions: for instance, across 
Europe, the cost of persistent asthma among 
those aged 15–64 years was estimated in 2010 
values at about €19.3 billion5; in Asia-Pacific 
region, the total annual per-patient soci-
etal costs of asthma varied from US$184 
in Vietnam to US$1189 in Hong Kong 
(2000 rates).6 Likewise, at national levels, 
asthma imposes considerable economic 
burden to the healthcare system besides 
its negative impact on the quality of life of 
individuals and families.7 8 For example, 
recent estimates found that asthma costs 
at least £1.1 billion per year to UK and its 
member nations,9 while in the USA the total 
cost attributed to asthma in 2007 was esti-
mated at about US$56 billion.10
Although varying estimates of asthma prev-
alence and burden at the national, regional 
and global levels have been reported in 
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Protocol
Strengths and limitations of this study
 ► To the best of our knowledge, this is the first 
systematic review to synthesise and critique 
existing models for estimating and/or projecting the 
prevalence and disease burden of asthma to scope 
the relevant evidence base.
 ► There is no geographical and language limitations.
 ► Comprehensive and highly sensitive search 
strategies, identification of studies from leading 
medical and public health databases, and 
involvement of a panel of expert will ensure quality 
of underlying evidence base.
 ► Panel of experts should be consulted due to lack of 
standard guidelines for evaluating models.
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the published literature,3 11–16 almost all appear to have 
major limitations in terms of inadequacy of the analytical 
approach used and lack of reproducibility.17–19 There is 
therefore a need for generating valid and reproducible 
estimates of disease prevalence and burden of asthma to 
inform evidence-based policy deliberations. Developing 
transparent processes for generating the national, regional 
and global estimates of prevalence and disease burden of 
asthma will thus enhance reproducibility across settings 
and will allow reliable projection of future estimates.
In healthcare policy, a model can be defined as a logical 
mathematical framework or analytical methodology that 
integrates theories and data to draw inferences regarding 
parameters of interest to clinicians and decision makers.20 21 
Models are widely used to estimate disease burden,9 22–24 
trend in prevalence25 26 and future projections27 of different 
epidemiological characteristics of asthma. Although 
current prevalence of asthma can be estimated without 
applying a model, many studies15 17 28–31 estimated asthma 
prevalence applying modelling techniques, particularly 
with the aim of adjusting for certain population char-
acteristics, such as age, sex, time, geography and other 
contextual parameters, which may vary across studies. For 
example, the International Study of Asthma and Allergies 
in Childhood Steering Committee applied generalised 
linear mixed model to estimate the global prevalence of 
asthma in order to adjust for within-country and between-
country variations.15 Adeloye et al17 applied a non-linear 
model to estimate regional (Africa) prevalence of asthma. 
The Global Burden of Disease studies also developed some 
computer based disease modelling tools (such as DisMod, 
DisMod-MR) to estimate the prevalence and burden of 
various diseases.28 32 However, existing models for esti-
mating and projecting prevalence and disease burden of 
asthma are in most cases poorly described, thereby limiting 
the opportunity to assess their reproducibility. In order to 
gain a better appreciation of the performance of existing 
models and their capacity for reproducibility in estimating 
the burden of asthma, a systematic appraisal of the under-
lying evidence base is required.33
objectives
The aims of this systematic review are to (1) systematically 
describe and critique the existing models for estimating 
and/or projecting the global, regional and national prev-
alence and disease burden of asthma in relation to their 
strengths, limitations and reproducibility, and (2) deter-
mine the appropriate models for estimating and projecting 




Any study that developed models for estimating and/or 
projecting prevalence and disease burden of asthma will be 
included in this review. Studies that estimated prevalence 
and disease burden without modelling will be excluded. 
Models that estimated individual risk rather than population 
benefits, such as decision analytic models and individual 
prognostic models, will be excluded. Moreover, studies with 
models that simply describe animals, clinical series and cell 
lines will be excluded. Comparative intervention studies 
will also be excluded. Potential sources of evidence such 
as original research articles and review articles, including 
systematic reviews, meta-analyses and meta-syntheses of 
observational studies, will be included.
Participants
Eligible participants in this review will include human 
populations of any age and either sex.
Years considered
We will include studies from January 1980 to April 2017. 
The start date has been set up from the time when model-
ling techniques started to be applied broadly to study the 
epidemic of non-communicable diseases.34
Setting
Research articles from any country and any setting 
(urban/rural) will be included in this review.
Language
There will be no language restrictions and, where possible, 
we will translate the literature published in languages 
other than English.
Information sources
Database searches and other sources to identify studies
We will conduct searches to identify both published and 
unpublished modelling studies in the following elec-
tronic databases: Medline, Embase, WHO Library and 
Information Services (library catalogue of books and 
reports) and Web of Science Core Collection. The refer-
ence lists of all the included papers will be searched for 
additional studies. We will also contact a panel of experts 
in an attempt to identify additional unpublished or in 
progress studies.
Search strategy
A comprehensive literature search will be undertaken to 
identify both published and unpublished (grey literature) 
primary studies as well as reviews. The search strategy has 
been developed for searching literature in Medline and 
Embase (see online supplementary appendix) in consul-
tation with a senior medical librarian at The University 
of Edinburgh, and this will be adapted in searching 
other databases. The search terms include the concepts 




The retrieved records from all databases will be exported 
to EndNote Library, which will be used throughout the 
review for study screening, deduplication and overall 
management of the retrieved records.
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Selection process
Two reviewers will independently check and screen 
the titles and abstracts of identified articles against the 
inclusion criteria. Full-text copies of potentially relevant 
studies will be obtained and assessed by two independent 
reviewers on the basis of their eligibility for inclusion. Any 
discrepancies will be resolved by discussion, and disagree-
ments will be arbitrated by a third reviewer.
Data extraction
A data extraction form will be used to extract relevant 
data from included studies. We have developed a draft 
data extraction form. During the review process, this 
draft will be refined and the data extraction form will be 
updated accordingly. The data extraction form will be 
pre-piloted prior to full use in the review. Data extraction 
will be performed independently by two reviewers.
data items
Information regarding different components of the 
models will be recorded to get a comprehensive picture 
of the models. The following data items will be extracted 
from each study: authors’ names; publication year; study 
aims; data source and time period; study population; 
asthma outcomes (prevalence/disease burden); study 
methodology; model type; model settings; model formu-
lation (structure, specification, assumptions, methods of 
model derivation, methods of parameter estimation and/
or projection, theoretical basis of the models) study vari-
ables; availability of data and codes; findings from the 
models; model fit information; key findings of the study; 
and identified research gaps. Information regarding 
the model availability, transparency, sensitivity analysis, 
model validation, addressing missing data, policymakers’ 
involvement, dissemination and expert involvement, 
limitation discussed and reproducibility of the model will 
also be extracted. Descriptive tables will be used to tabu-
late these items. The systematic review will be reported 
following the guidelines of the Preferred Reporting Items 
for Systematic review and Meta Analysis (PRISMA) check-
list (see online supplementary material).35
outcomes and prioritisation
The outcomes that are of interest include prevalence and 
disease burden of asthma. There are various measures 
available to quantify disease burden. All the established 
measures of disease burden will be considered in this 
review. Primary and secondary outcomes are categorised 
as follows.
Primary outcomes
1. Prevalence of asthma.
2. Different measures of disease burden of asthma. 
The measures are: DALYs, YLDs, mortality, 
healthcare cost (cost of illness, drug cost, hospital 
cost/hospitalisation cost), life expectancy, primary 
care, ambulatory care, emergency visit, absentees, 
years life lost, potential years of life lost, healthy 
years of life lost, active life expectancy, disability-free 
life expectancy, disability-adjusted life expectancy, 
healthy life expectancy, and so on.
Secondary outcomes
1. Incidence of asthma.
Risk of bias in individual studies
To the best of our knowledge, there is no existing quality 
appraisal tool to assess quality of models. So we have 
drawn on first principles and adapted relevant sections 
from pertinent reporting guidelines36 and other guide-
lines for good practice in modelling studies20 21 37 38 to 
develop our own model evaluation framework. This will 
involve independent assessment of the strengths and 
limitations of the models on the basis of model structure, 
specification, assumptions, sensitivity analysis, model 
validation, dealing with missing data, theoretical basis of 
the models, incorporation of confounding factors and 
lag times, and whether potential methodological limita-
tions are described. Reproducibility of the model will be 
assessed on the basis of availability of the models, data, 
codes and methods of parameter estimation. 
To evaluate the models used in included studies and 
to identify the best models, we have prepared a check-
list of items and formulated a scoring strategy (see 
online supplementary appendix) that we will use for 
these purposes. Prior to use of the checklist, we plan to 
consult with a panel of experts in the field of modelling 
studies to gain their insights and criticisms of the check-
list; we will then integrate feedback collated in preparing 
the final version of the checklist to be used in our study.
data synthesis
A tabular summary of the data will be presented to 
summarise overall evidence. A detailed critical narrative 
synthesis of the models will be undertaken regarding 
their strengths, limitations and reproducibility.
PRoToCol RegISTRATIon
A detailed protocol for the systematic review will be 
registered with the International Prospective Register 
of Systematic Reviews prior to commencing the review 
according to the PRISMA-Protocols 2015 statement.39
ConCluSIonS
To the best of our knowledge no review has been under-
taken yet to appraise the models for estimating and 
projecting the global, regional and national prevalence 
and disease burden of asthma. This systematic review is 
therefore the first study to synthesise existing models for 
estimating and projecting prevalence and disease burden 
of asthma. The review will also map the appropriate 
models that will subsequently be used to obtain current 
estimates and project future trend of global, regional and 
national prevalence and disease burden of asthma.
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eThICS And dISSeMInATIon
We will not collect any primary data for this review, and 
hence there is no need for formal National Health Service 
Research Ethics Committee review. This work is however 
subject to Institutional Review Board oversight by The 
University of Edinburgh’s Centre for Population Health 
Sciences. Findings from the review will be presented at 
scientific conferences and be published in the peer-re-
viewed scientific journal.
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